US · Healthcare · Biotechnology
EPS came in at -2.88 against a street estimate of -0.65 — a miss of 343.1%.
Analysts rate Kardigan, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $42.25.
| Fund | Stake |
|---|---|
| SCHF (GPE), LLC | 18.09% |
| FMR Inc | 9.53% |
| Perceptive Advisors LLC | 8.77% |
| T. Rowe Price Investment Management,Inc. | 4.50% |
| Capital Research Global Investors | 3.85% |
| JPMorgan Chase & Co | 1.92% |
| AllianceBernstein L.P. | 1.64% |
| Liberty Mutual Group Asset Management Inc. | 1.28% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 HEADLINE NUMBERS • Kardigan, Inc. (Nasdaq: KARD) appointed Kristin Reinke as a Class I director effective September 29, 2026. • Reinke will chair th | 2026-09-30 |
| Quarterly report · Q2 2026 KARDIGAN, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $384.0 million in cash and equivalents as of J | 2026-08-11 |
| Results announced · Q3 2026 KARDIGAN Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $660.7 million as of June 30, 2026, up from $335.5 million at December | 2026-08-11 |
| Charter / bylaws change · Q2 2026 KARDIGAN, INC. (KARD) - 8-K SUMMARY HEADLINE NUMBERS • Company completed its initial public offering (IPO) on June 22, 2026 • Trading symbol: KARD o | 2026-06-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kardigan, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.